183 related articles for article (PubMed ID: 24517435)
1. Biomarkers and possible mechanisms of operational tolerance in kidney transplant patients.
Dugast E; Chesneau M; Soulillou JP; Brouard S
Immunol Rev; 2014 Mar; 258(1):208-17. PubMed ID: 24517435
[TBL] [Abstract][Full Text] [Related]
2. Operational tolerance: past lessons and future prospects.
Levitsky J
Liver Transpl; 2011 Mar; 17(3):222-32. PubMed ID: 21384504
[TBL] [Abstract][Full Text] [Related]
3. Tolerance in Solid-Organ Transplant.
Fine RN
Exp Clin Transplant; 2016 Nov; 14(Suppl 3):1-5. PubMed ID: 27805501
[TBL] [Abstract][Full Text] [Related]
4. Immunoregulation and tolerance.
Knechtle SJ
Transplant Proc; 2010 Nov; 42(9 Suppl):S13-5. PubMed ID: 21095443
[TBL] [Abstract][Full Text] [Related]
5. Monitoring alloimmune response in kidney transplantation.
Bestard O; Cravedi P
J Nephrol; 2017 Apr; 30(2):187-200. PubMed ID: 27245689
[TBL] [Abstract][Full Text] [Related]
6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
[TBL] [Abstract][Full Text] [Related]
7. Conclusions from the symposium.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S47-8. PubMed ID: 21095453
[TBL] [Abstract][Full Text] [Related]
8. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
9. Immunological biomarkers of tolerance in human kidney transplantation: An updated literature review.
Mirzakhani M; Shahbazi M; Oliaei F; Mohammadnia-Afrouzi M
J Cell Physiol; 2019 May; 234(5):5762-5774. PubMed ID: 30362556
[TBL] [Abstract][Full Text] [Related]
10. Monitoring the operationally tolerant liver allograft recipient.
Castellaneta A; Thomson AW; Nayyar N; de Vera M; Mazariegos GV
Curr Opin Organ Transplant; 2010 Feb; 15(1):28-34. PubMed ID: 19890211
[TBL] [Abstract][Full Text] [Related]
11. Late steroid withdrawal after ABO blood group-incompatible living donor kidney transplantation: high rate of mild cellular rejection.
Oettl T; Zuliani E; Gaspert A; Hopfer H; Dickenmann M; Fehr T
Transplantation; 2010 Mar; 89(6):702-6. PubMed ID: 20010328
[TBL] [Abstract][Full Text] [Related]
12. Tolerance induction.
Kupiec-Weglinski JW
Curr Opin Organ Transplant; 2008 Aug; 13(4):331-2. PubMed ID: 18685325
[No Abstract] [Full Text] [Related]
13. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes.
Baron D; Giral M; Brouard S
Transpl Int; 2015 Aug; 28(8):938-59. PubMed ID: 25851900
[TBL] [Abstract][Full Text] [Related]
14. What do we know about the clinical impact of complete withdrawal of immunosuppression in liver transplantation?
Pons JA; Revilla Nuin B; Ramírez P; Baroja Mazo A; Martínez Alarcón L; Robles R; Sánchez Bueno F; Rios A; Cascales Campos P; Parrilla P
Transplant Proc; 2012; 44(6):1530-2. PubMed ID: 22841204
[TBL] [Abstract][Full Text] [Related]
15. The Importance of Bringing Transplantation Tolerance to the Clinic.
Cosimi AB; Ascher NL; Emond JC; Kaufman DB; Madsen JC; Miller J; Monaco AP; Montgomery RA; Newell KA; Sánchez-Fueyo A; Sarwal MM; Scandling JD; Strober S; Todo S; Weir MR; Sachs DH
Transplantation; 2021 May; 105(5):935-940. PubMed ID: 33901128
[No Abstract] [Full Text] [Related]
16. The use of novel diagnostics to individualize immunosuppression following transplantation.
Schlickeiser S; Boës D; Streitz M; Sawitzki B
Transpl Int; 2015 Aug; 28(8):911-20. PubMed ID: 25611562
[TBL] [Abstract][Full Text] [Related]
17. Increasing relevance of donor-specific antibodies in antibody-mediated rejection.
Zito A; Schena A; Grandaliano G; Gesualdo L; Schena FP
J Nephrol; 2013; 26(2):237-42. PubMed ID: 23475460
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
Kuypers DR
Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
[No Abstract] [Full Text] [Related]
19. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression in maintenance heart transplant patients: results at 2 years.
Engelen MA; Amler S; Welp H; Vahlhaus C; Gunia S; Sindermann JR; Rothenburger M; Stypmann J
Transplantation; 2011 May; 91(10):1159-65. PubMed ID: 21478817
[TBL] [Abstract][Full Text] [Related]
20. Can the early elimination of calcineurin inhibitors result in clinical benefits?
Weir MR
Transplant Proc; 2010 Nov; 42(9 Suppl):S16-20. PubMed ID: 21095444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
